| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Persicogenin targets multiple pathways involved in cancer cell proliferation and survival. It inhibits the proliferation of mouse tsFT210 cancer cells and mainly arrests the cell cycle at the G2/M phase in a dose-dependent manner. The compound activates the Fas/Fas ligand apoptosis system, which is crucial for programmed cell death in cancer cells. Network pharmacology analysis has identified potential targets including EGFR, VEGFA, and ESR1, which are involved in various signaling pathways related to cancer and gastrointestinal health. Persicogenin also exhibits antileishmanial activity.
|
|---|---|
| ln Vitro |
In vitro, Persicogenin inhibits the proliferation of mouse tsFT210 cancer cells and mainly arrests the cell cycle at the G2/M phase in a dose-dependent manner. The compound exhibits moderate antimycobacterial activity against Mycobacterium tuberculosis with an MIC value of 174.8 μM. It also shows antileishmanial activity and anticancer activity. The compound activates the Fas/Fas ligand apoptosis system. These activities confirm Persicogenin's potential as a multi-target anticancer and antimicrobial agent.
|
| ln Vivo |
Specific in vivo data for Persicogenin are limited in the available literature. Given its in vitro anticancer activity and cell cycle arrest properties, the compound has potential for in vivo efficacy studies in mouse xenograft models of various cancers. Its antileishmanial activity suggests potential for in vivo studies in Leishmania infection models. Network pharmacology analysis suggests potential therapeutic effects in treating constipation, indicating possible applications in gastrointestinal research. However, specific published in vivo protocols are not available.
|
| Enzyme Assay |
The anticancer activity is assessed using cell proliferation assays. Mouse tsFT210 cancer cells or other cancer cell lines are cultured in appropriate media and treated with Persicogenin at various concentrations for 24-72 hours. Cell viability is measured using MTT, CCK-8, or CellTiter-Glo assays. Cell cycle distribution is analyzed by flow cytometry after propidium iodide staining, with the percentage of cells in G2/M phase determined. Apoptosis is assessed by measuring caspase-3/7 activity, Annexin V/PI staining, or DNA fragmentation. Fas/Fas ligand pathway activation is assessed by Western blot.
|
| Cell Assay |
For antimicrobial testing, Mycobacterium tuberculosis and other pathogens are cultured in appropriate media. Persicogenin is added at various concentrations, and bacterial growth is monitored by measuring optical density or by colony counting. The MIC is determined as the lowest concentration that inhibits visible growth. For antileishmanial activity, Leishmania parasites are cultured and treated with the compound, with parasite viability assessed using appropriate assays. Cytotoxicity in mammalian cells is assessed using standard viability assays.
|
| Animal Protocol |
In vivo studies for Persicogenin would be conducted in appropriate animal models. For anticancer activity, mouse xenograft models using cancer cell lines would be employed. The compound would be administered via oral gavage or intraperitoneal injection, and tumor volumes would be measured. For antileishmanial studies, Leishmania-infected mouse models would be used, with parasite burden and clinical signs assessed. For gastrointestinal studies, constipation models would be used to evaluate therapeutic effects. However, specific published protocols are not available.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for Persicogenin are not reported. As a flavonoid with moderate lipophilicity, the compound is expected to have reasonable oral absorption. The compound's molecular weight is approximately 316 g/mol. Pharmacokinetic studies would be required to determine parameters such as half-life, Cmax, oral bioavailability, and tissue distribution in animal models. The compound's stability in biological matrices and protein binding properties would also require characterization.
|
| Toxicity/Toxicokinetics |
Toxicological data for Persicogenin are limited. As a natural product from various plant sources with traditional uses, the compound is generally considered to have a moderate safety profile at the concentrations used in research. However, comprehensive toxicology studies including acute, subchronic, and genotoxicity assessments have not been reported. The compound should be handled with appropriate safety precautions in laboratory settings.
|
| References | |
| Additional Infomation |
3',5-Dihydroxy-4',7-Dimethoxyflavanone is an ether compound belonging to the flavonoid class. It has been reported that aucubin is found in peach (Prunus persica), jasmine (Chromolaena odorata), and other organisms with relevant data.
Persicogenin is a natural O-methylated flavonoid with anticancer, antimutagenic, and antileishmanial activities. It inhibits cell proliferation and arrests the cell cycle at G2/M phase, activates Fas/Fas ligand apoptosis, and shows antimycobacterial activity (MIC 174.8 μM). No clinical trials or approvals exist. For research use only. |
| Molecular Formula |
C17H16O6
|
|---|---|
| Molecular Weight |
316.30534
|
| Exact Mass |
316.095
|
| CAS # |
28590-40-1
|
| PubChem CID |
320054
|
| Appearance |
White to off-white solid
|
| Density |
1.358g/cm3
|
| Boiling Point |
574.9ºC at 760 mmHg
|
| Melting Point |
163 - 164 °C
|
| Flash Point |
215ºC
|
| Vapour Pressure |
8.12E-14mmHg at 25°C
|
| Index of Refraction |
1.619
|
| LogP |
2.821
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
23
|
| Complexity |
427
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(C=C(C=C1)C2CC(=O)C3=C(C=C(C=C3O2)OC)O)O
|
| InChi Key |
LWBHKKLWSUFUNZ-HNNXBMFYSA-N
|
| InChi Code |
InChI=1S/C17H16O6/c1-21-10-6-12(19)17-13(20)8-15(23-16(17)7-10)9-3-4-14(22-2)11(18)5-9/h3-7,15,18-19H,8H2,1-2H3/t15-/m0/s1
|
| Chemical Name |
(2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-methoxy-2,3-dihydrochromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~158.07 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.95 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.95 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: 1.25 mg/mL (3.95 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1615 mL | 15.8073 mL | 31.6146 mL | |
| 5 mM | 0.6323 mL | 3.1615 mL | 6.3229 mL | |
| 10 mM | 0.3161 mL | 1.5807 mL | 3.1615 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
